What Race Is Cystic Fibrosis Most Common In?

Cystic fibrosis (CF) is most common in white people whose families come from Northern Europe. But it is not a white-only disease, and it turns up in Black, Hispanic, Asian and Middle Eastern families too.1PubMed Central. Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment In people who aren’t white, CF is more likely to be missed, because the usual tests look for gene changes that are most common in Europeans.2PubMed Central. Detection of disease‐causing CFTR variants in state newborn screening programs

How Common Cystic Fibrosis Is in Each Group

Each figure estimates how many births are affected, and that depends on how many cases were actually found. The same group can look very different from country to country: the UK figure for South Asians is far higher than Canada’s, which suggests estimates depend partly on how hard doctors look and on cases that go undiagnosed.

The gap between groups comes down to carriers. CF happens when a child inherits a faulty copy of the CF gene from both parents. A parent with one faulty copy is a carrier and is usually healthy. About 1 in 25 to 30 white people are carriers, while carrier rates are lower in other groups.6Genetics in Medicine. Cystic fibrosis population carrier screening: Here at last—Are we ready? Two carrier parents have a 1 in 4 chance, with each pregnancy, of having a child with CF.

A lower group rate describes a population, not a person. It does not lower the 1 in 4 chance for a couple who both carry the gene. A relative with CF, or a relative who is a carrier, says far more about your family’s risk than race does.

In the US, of about 53,900 people born with CF since 1968, about 45,700 were white non-Hispanic, 4,780 were Hispanic and 2,480 were Black.7PubMed Central. Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020 The recent picture is different. Among babies diagnosed through US newborn screening from 2010 to 2018, about 13% were Hispanic and 6 to 7% were Black.1PubMed Central. Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment

Why Cystic Fibrosis Is Most Common in Europeans

CF is the most common deadly single-gene disease in people of European descent, with over 2% carrying it.8PubMed Central. Evaluating candidate agents of selective pressure for cystic fibrosis A gene this harmful usually stays rare, unless carriers gained some benefit from having one copy. Scientists once thought carriers resisted cholera or typhoid, but those diseases weren’t strong enough to explain today’s numbers.8PubMed Central. Evaluating candidate agents of selective pressure for cystic fibrosis The tuberculosis epidemic in Europe from the 1600s could have been, by one model.8PubMed Central. Evaluating candidate agents of selective pressure for cystic fibrosis

The logic runs like this. If carriers survived an epidemic more often than non-carriers, they lived to have more children, and those children inherited the gene. The benefit applied to people with one copy, while the unlucky child who inherited two copies developed CF, so the gene stayed in the population despite the cost. Over many generations, that balance could push the gene to the high carrier rate seen in Europe today. This is a leading theory, not settled fact, and researchers still debate which disease, if any, drove it.

Different Gene Changes in Different Backgrounds

The single most common CF gene change, called F508del, is present in about 65% of European cases.9eBioMedicine. Genome Database Analysis Suggests Cystic Fibrosis is More Globally Distributed Than Previously Believed It is found in only about 9% of East Asian cases and 27 to 33% of African, South Asian and Middle Eastern cases.9eBioMedicine. Genome Database Analysis Suggests Cystic Fibrosis is More Globally Distributed Than Previously Believed

Other groups carry their own common changes. African Americans have a set that traces back to Africa, and one of them, 3120+1G>A, accounts for about 12% of CF genes in African Americans.10PubMed Central. Identification of common cystic fibrosis mutations in African-Americans with cystic fibrosis increases the detection rate to 75% Hispanic families of Ecuadorian and Mexican ancestry often carry changes that are rare elsewhere in the US.11PubMed. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine In people of African descent in the Americas, over half of CF gene changes remained unidentified in published data.12PubMed. Cystic Fibrosis in the African Diaspora

A test built mainly around the most common CF gene change works well where it is common and poorly where it is rare, so the same test gives different reassurance to different families. A person with CF has two gene changes, one from each parent, so finding only one does not complete the picture.

Marriage between relatives also shapes the picture. In one Saudi group, 85% of people with CF had parents who were related, versus about 50% of the country overall.13PubMed Central. Geographic distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Saudi Arabia Relatives are more likely to share the same rare change inherited from a common ancestor. When both carry it, a child can receive it from both sides, which is exactly what CF requires. So rare local changes get passed on in both copies, making CF common there despite being rare elsewhere.13PubMed Central. Geographic distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Saudi Arabia

A person’s background can suggest which changes are more likely, but it cannot say which ones are actually in their DNA. People of mixed or unknown ancestry need a broad test, ideally one that reads the whole gene.

Why Newborn Screening Can Miss CF in Non-White Babies

US newborn screening first measures a protein in the blood, then checks the baby’s blood spot for a list of known CF gene changes. Those lists were built around European genes. They found at least one change in up to 97% of white babies with CF, but in as few as 42% of Black, Asian and Hispanic babies.2PubMed Central. Detection of disease‐causing CFTR variants in state newborn screening programs On a common 23-change panel, 28% of Asian and 18% of Black people with CF had no listed change, versus 3% of white people.14Genetics in Medicine. Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients A normal screen is therefore less reassuring for a non-white baby.2PubMed Central. Detection of disease‐causing CFTR variants in state newborn screening programs

Even after a normal screen, watch for salty-tasting skin, poor weight gain despite good feeding, greasy and bulky stools, and a cough that won’t go away. Tell the doctor plainly that newborn screening can miss CF in some backgrounds, so a normal screen shouldn’t close the question. Ask for a sweat test, since it measures salt directly and doesn’t depend on which gene changes are on a screening list.

The opposite problem shows up in Black babies: false alarms. The first screening step measures a blood protein that is raised in babies with CF, and a result above a cutoff triggers more testing. Black babies tend to have higher levels of this protein,15PubMed. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening so more healthy babies cross the cutoff. In New York, only about 3 in 1,000 positive screens in Black babies turned out to be CF.16PubMed. Elevated IRT levels in African-American infants: implications for newborn screening in an ethnically diverse population A repeat protein test at 2 to 3 weeks can show whether the level has fallen back, which cuts these false alarms and spares many families a full workup.16PubMed. Elevated IRT levels in African-American infants: implications for newborn screening in an ethnically diverse population

Most babies with a positive screen don’t have CF, so a positive result is a reason for follow-up, not a diagnosis. The next step is a sweat test, which confirms or rules out CF.

Diagnosis Later in Life

A sweat test measures the salt in a person’s sweat; a result of 60 or above usually means CF. But 14% of Asian patients with CF had results below 60, versus 6% of others.17PubMed. Ethnicity impacts the cystic fibrosis diagnosis: A note of caution And 55% of British Asian patients with CF have no gene change on the routine screening list.17PubMed. Ethnicity impacts the cystic fibrosis diagnosis: A note of caution Many Chinese patients show up with male infertility from a missing sperm duct, or with a salt imbalance, rather than lung problems.18PubMed Central. Distinct CFTR Mutation Spectrum and Atypical Clinical Presentations in Chinese Patients with Cystic Fibrosis

These presentations get missed in part because doctors who think of CF as a childhood lung disease of white people may not consider it in an adult with other symptoms. Some gene changes cause a milder form that affects a single organ, so lung symptoms may be minor or absent. A sweat result just under the usual cutoff does not rule out CF when the rest of the picture fits.

A borderline sweat test combined with symptoms deserves full gene sequencing, which reads the whole CFTR gene and can find rare changes that a standard list misses. A thorough workup usually repeats or confirms a borderline sweat test at a CF center. Unexplained infertility in a man, especially with a missing sperm duct, can be a clue even without lung problems. Repeated lung infections, chronic sinus trouble or unexplained poor digestion are other reasons to ask whether CF has been properly ruled out. If a doctor dismisses CF because of the patient’s race, it is reasonable to ask for the testing anyway, since CF occurs in every group.

Carrier Testing Before Pregnancy

Shorter carrier panels catch about 96% of carriers of Northern European descent but only 64% of South Asian ones.19PubMed. Cystic fibrosis carrier screening in Australia: comparing sequencing and targeted panels across diverse ancestries After a negative test, a South Asian person still has about a 1 in 179 chance of being a carrier, versus 1 in 546 for Northern Europeans.19PubMed. Cystic fibrosis carrier screening in Australia: comparing sequencing and targeted panels across diverse ancestries Common panels also missed 37 to 47% of South Asian patients with CF.4PubMed. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis

So ask the clinic or lab whether your test sequences the whole gene or checks a short list, and how many gene changes it covers. A broad panel gives the most information for mixed or unknown ancestry,20Genetics in Medicine. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel and it helps to tell your provider your family’s ancestry, including any that is uncertain, so they can judge how well the panel fits. A relative with CF or a known carrier changes the plan, because testing for that family’s specific change can be done.

If one partner is a carrier, the other should be tested, and full gene sequencing is the safer choice if their ancestry is not Northern European. A genetic counselor can turn those percentages into a clear picture of the couple’s real risk. If both partners are carriers, prenatal testing during pregnancy is an option, and the couple can discuss other choices with their care team.

Do CF Treatments Work for Every Background

CFTR modulators are pills that fix the faulty CF protein for specific gene changes. Each one is designed to work on the protein made by particular changes, so a drug that suits one change may do nothing for another. About 92% of white patients qualify for at least one, versus about 76% of Hispanic and 70% of Black patients.21PubMed Central. Cystic Fibrosis Patients of Minority Race and Ethnicity Less Likely Eligible for CFTR Modulators Based on CFTR Genotype And 41 to 49% of South Asian patients don’t qualify.4PubMed. CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis Some common Hispanic gene changes have no approved targeted drug.11PubMed. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine Many changes common outside Europe were studied late, so some groups have fewer options for now.

Patients who don’t qualify still have real help. Standard CF care includes airway clearance, digestive enzymes, nutrition support and treating infections early. Clinical trials are testing drugs for rarer gene changes, and a CF center can tell patients which ones might apply. Ask the care team whether your exact gene changes have been studied, since eligibility can change as new data arrive.